Skip to main content
OpenTrials

Clinical trial condition

Urologic Neoplasms

Explore clinical trials studying Urologic Neoplasms. Study availability and eligibility vary by location and protocol.

2,957 public trials 633 recruiting studies
Refine in advanced search Browse all conditions

Urologic Neoplasms trial results

Completed

S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

NCT00445601

Conditions
Bladder Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +9 more
Locations
  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center Los Angeles, California, United States
  • University of California Davis Cancer Center Sacramento, California, United States
  • University of Colorado Cancer Center at UC Health Sciences Center Aurora, Colorado, United States
View all 70 locations
View Trial Details
Completed

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

NCT00078858

Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adenocarcinoma, Adult Acute Lymphoblastic Leukemia in Remission, +220 more
Locations
  • Stanford University Hospitals and Clinics Stanford, California, United States
  • Rocky Mountain Cancer Centers-Midtown Denver, Colorado, United States
  • Emory University/Winship Cancer Institute Atlanta, Georgia, United States
  • OHSU Knight Cancer Institute Portland, Oregon, United States
View Trial Details
Completed

Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

NCT01550367

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Loyola University Chicago Maywood, Illinois, United States
  • Indiana University Simon Cancer Center Indianapolis, Indiana, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Dartmouth-Hitchcock Medical Center Hanover, New Hampshire, United States
View Trial Details
Completed

A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)

NCT00978250

Conditions
Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, +21 more
Locations
  • University of California, Davis Davis, California, United States
  • City of Hope National Medical Center Duarte, California, United States
  • City of Hope Medical Group South Pasadena, California, United States
  • National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States
View Trial Details
Completed

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma

NCT01984242

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • HonorHealth Research Institute - Bisgrove Scottsdale, Arizona, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UCLA Los Angeles, California, United States
  • University of California San Francisco, California, United States
View all 45 locations
View Trial Details
Completed

Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

NCT00027820

Conditions
Adenocarcinoma, Adult Acute Myeloid Leukemia in Remission, Anemia, +72 more
Locations
  • University of Arizona Health Sciences Center Tucson, Arizona, United States
  • Stanford University Hospitals and Clinics Stanford, California, United States
  • Emory University/Winship Cancer Institute Atlanta, Georgia, United States
  • OHSU Knight Cancer Institute Portland, Oregon, United States
View Trial Details
Completed

Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer

NCT01445379

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +31 more
Locations
  • National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details
Completed

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

NCT00722553

Conditions
Bladder Cancer, Bladder Neoplasm, Carcinoma, +20 more
Locations
  • The University of Arizona Health Sciences Center Tucson, Arizona, United States
  • Peachtree Hematology/Oncology Consultants Atlanta, Georgia, United States
  • University of Rochester Cancer Center Rochester, New York, United States
  • University of Utah, Huntsman Cancer Institute Salt Lake City, Utah, United States
View all 19 locations
View Trial Details

Related conditions